• Not Particularly For A Pandemic, But The Supply Chain Was Ready

    A discussion on lessons learned from the pandemic featured Remo Colarusso, Vice President, Janssen Supply Chain, Johnson & Johnson, and Ken Kent, Senior Vice President, Chemical Development and Manufacturing Operations, Gilead Sciences, at a recent DCAT Virtual Week event.

  • Leaders Have An Appetite For Adaptability When Outsourcing

    In part one - "Five Maxims For Outsourcing Success" - we tackled Lisa Wyman's first three of five tenets to better outsource by. Here we explore her belief that leveraging capabilities and capacities of CDMOs is predicated on an appetite for adaptability and flexibility, and that is exhibited as a quality of leadership.

  • An All-Canada COVID-19 Vaccine Solution

    The story of how Providence Therapeutics, a Calgary, Ontario-based, emerging mRNA biopharma, came to achieve such notoriety is an interesting one that includes a pivot from its core therapeutic focus, the hiring of an American as company president, and the creation of a CDMO.

  • Ensysce Biosciences CEO Talks SPAC

    Ensysce Biosciences CEO Lynn Kirkpatrick knows every organization is different, but believes any CEO of a biotech today might consider going the special purpose acquisition company (SPAC) route to financially fuel the organization. Here’s how and why she and Ensysce decided to move forward.

  • SPACs, Opioids, and COVID: Ensysce Biosciences Making “Virtual” History

    If Ensysce Biosciences were a ball of yarn, we’d be unwinding it for hundreds of miles from its location in La Jolla, California. We’d unravel solid oral dose programs – new opioids and a COVID treatment, an all-outsourced model, and now one of the first biotechs to go public via a SPAC (special purpose acquisition company).

  • Should Your CDMO Become A 503B?

    A reader pulled me down an Alice-In-Wonderland rabbit hole. I’m glad she did, though. If you read the headline above and thought, “What exactly is a 503B?” you’ll be glad, too.  

  • Position Your CDMO For Competitive Advantage

    “Outsourcing is really about positioning your CDMO to your competitive advantage,” says Lisa Wyman, SVP technical operations and quality at Acceleron Pharma.

  • The Challenges Provided Us A Deeper Meaning

    The past year of travel and other restrictions have skewed the biopharma outsourcer’s mantra of “trust but verify” to a heavier weight on the first of those two components. For some, this was easier to deal with than others.

  • Can Your CDMO Relationships Survive Another “Virtual” Year?

    Lori Hoffman, head of alliance management, Slayback Pharma; and Greg Birrer, quality head, Elusys Therapeutics, talk about how the pandemic has affected CDMOs.

  • What’s A “Biopharma CDMO”?

    In part two of my exclusive interview with Phlow Corporation's CEO Dr. Eric Edwards, we turn our attention to biopharma business models and CDMO partnerships.


Louis Garguilo

Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.